A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Randomized, Open-Label, Multi-Center Trial Comparing Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Subjects With Newly Diagnosed Multiple Myeloma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00097981
• Other study ID #: CR004579
• Secondary ID: DO04-23-006
• Status: Completed
• Phase: Phase 3
• First received: December 1, 2004
• Last updated: September 25, 2013
• Start date: January 2005
• Est. completion date: October 2009

Study information

• Verified date: September 2013
• Source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if Thalidomide + Dexamethasone or DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone is more effective in treating newly diagnosed patients with multiple myeloma. The number of patients whose multiple myeloma disappears for a period of time (complete Response) will be studied to make the determination of which treatment is more effective.

Description:

This is a multi-center, open-label (all people know the identity of the intervention), randomized (the study medication is assigned by chance) study to compare the safety and effectiveness of Thalidomide + Dexamethasone versus DOXIL (doxorubicin HCl liposome injection) + Thalidomide + Dexamethasone in patients with newly diagnosed multiple myeloma. Treatments are administered in 28-day cycles. Patients will receive 4 to 12 treatment cycles, depending on the response of their multiple myeloma to the treatment (measured according to the European Group for Blood and Marrow Transplant Response Criteria). Patients will have additional tests that include Multiple Gated Acquisition (MUGA) scans or echocardiograms to assess the patients for potential cardiotoxicity that could be related to treatment with DOXIL (doxorubicin HCl liposome injection). Maximum duration of study participation for each participant will be 48 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 225
• Est. completion date: October 2009
• Est. primary completion date: October 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Previously untreated, histologically confirmed multiple myeloma (per International Myeloma Working Group [IMWG] criteria

• Eastern Cooperative Oncology Group (ECOG) status 0-2

• Adequate absolute neutrophil count (ANC), platelet count and hemoglobin

• Adequate serum calcium

• Enrollment in System for Thalidomide Education and Prescribing Safety Program (S.T.E.P.S.)

Exclusion Criteria:

• No treatment with dexamethasone for multiple myeloma

• No peripheral neuropathy of Grade 2 or higher

• No Left Ventricular Ejection Fraction (LVEF) of less than 45 percentage

• No history of life-threatening thromboembolic events of any kind (ie, myocardial infarction, pulmonary embolism, stroke or others), within 1 year before enrollment in the study

• No deep vein thrombosis (DVT) within 1 year of enrollment

• No current anticoagulation for DVT

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• Thalidomide
Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
• Dexamethasone
Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
• DOXIL
DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete Response Rate: Number of Participants Who Achieved a Complete Response	Complete response rate to study medication is defined as number of participants who acheived complete response by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + plus no increase in size or number of lytic bone lesions. Complete response was assessed at the beginning of every treatment cycle prior to treatment, starting at Cycle 2.	From Cycle 2 until 28 days following completion of treatment	No
Secondary	Overall Response: Number of Participants Who Achieved a Complete Response (CR) or Partial Response (PR)	Overall response to study medication is defined as number of participants who acheived a complete response (CR) or partial response (PR) by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + plus no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.	From Cycle 2 until 28 days following completion of treatment	No
Secondary	Time to 1st Response	Time to first response was defined as the interval from date of randomization to date of achieving a partial response (PR) or better according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.	From Cycle 2 until 28 days following completion of treatment	No
Secondary	Time to Progression	Time to progression is the interval between the date of randomization until disease progression or death due to progression.	From randomization until death or as assessed up to 2 years post last participant last treatment visit	No
Secondary	Overall Survival: Number of Participants Died Due to Any Cause		From randomization until death or as assessed up to 2 years post last participant last treatment visit	No
Secondary	Transplantation: Number of Participants Who Underwent Transplantation (Peripheral Stem Cell / Bone Marrow)		From randomization until death or as assessed up to 2 years post last participant last treatment visit	No
Secondary	Engraftment: Number of Participants Who Underwent Engraftment	Engraftment is the process of transplanted stem cells reproducing new cells.	From randomization until death or as assessed up to 2 years post last participant last treatment visit	No